Literature DB >> 21586355

Adenosine receptors in health and disease.

Stefania Gessi1, Stefania Merighi, Katia Varani, Pier Andrea Borea.   

Abstract

The adenosine receptors A(1), A(2A), A(2B), and A(3) are important and ubiquitous mediators of cellular signaling, which play vital roles in protecting tissues and organs from damage. In particular, adenosine triggers tissue protection and repair by different receptor-mediated mechanisms, including an increase of oxygen supply/demand ratio, preconditioning, anti-inflammatory effects, and stimulation of angiogenesis. Considerable advances have been recently achieved in the pharmacological and molecular characterization of adenosine receptors, which have been proposed as targets for drug design and discovery. At the present time, it can be speculated that adenosine A(1), A(2A), A(2B), and A(3) receptor-selective ligands may show utility in the treatment of pain, ischemic conditions, glaucoma, asthma, arthritis, cancer, and other disorders in which inflammation is a feature. This chapter documents the present state of knowledge of adenosine receptors' role in health and disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21586355     DOI: 10.1016/B978-0-12-385526-8.00002-3

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  29 in total

Review 1.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Authors:  Kenneth A Jacobson; Ramachandran Balasubramanian; Francesca Deflorian; Zhan-Guo Gao
Journal:  Purinergic Signal       Date:  2012-02-29       Impact factor: 3.765

Review 2.  The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.

Authors:  Anna Eisenstein; Shenia Patterson; Katya Ravid
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

3.  Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists.

Authors:  Francesco Sirci; Laura Goracci; David Rodríguez; Jacqueline van Muijlwijk-Koezen; Hugo Gutiérrez-de-Terán; Raimund Mannhold
Journal:  J Comput Aided Mol Des       Date:  2012-10-12       Impact factor: 3.686

4.  Adenosine deaminase deficiency: unanticipated benefits from the study of a rare immunodeficiency.

Authors:  Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

5.  Potent and multiple regulatory actions of microglial glucocorticoid receptors during CNS inflammation.

Authors:  M Á Carrillo-de Sauvage; L Maatouk; I Arnoux; M Pasco; A Sanz Diez; M Delahaye; M T Herrero; T A Newman; C F Calvo; E Audinat; F Tronche; S Vyas
Journal:  Cell Death Differ       Date:  2013-09-06       Impact factor: 15.828

Review 6.  Purinergic signaling in the retina: From development to disease.

Authors:  Ana Lucia Marques Ventura; Alexandre Dos Santos-Rodrigues; Claire H Mitchell; Maria Paula Faillace
Journal:  Brain Res Bull       Date:  2018-11-17       Impact factor: 4.077

7.  Adenosine A2A receptor and TNF-α regulate the circadian machinery of the human monocytic THP-1 cells.

Authors:  Miguel Perez-Aso; Jessica L Feig; Aránzazu Mediero; Mediero Aránzazu; Bruce N Cronstein
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 8.  Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Authors:  K Janes; A M Symons-Liguori; K A Jacobson; D Salvemini
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

9.  Effects of Long-Term Caffeine Consumption on the Adenosine A1 Receptor in the Rat Brain: an In Vivo PET Study with [18F]CPFPX.

Authors:  Danje Nabbi-Schroeter; David Elmenhorst; Angela Oskamp; Stefanie Laskowski; Andreas Bauer; Tina Kroll
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

10.  Adenosine: essential for life but licensed to kill.

Authors:  Vivian Gama; Mohanish Deshmukh
Journal:  Mol Cell       Date:  2013-05-09       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.